Report: Johnson & Johnson wants to sell its stroke business for more than $1B
One of the world’s largest healthcare technology companies is considering a sale of its stroke business, according to a new report from Financial Times. The asking price is believed to be more than $1 billion.
According to multiple anonymous sources familiar with the matter, Johnson & Johnson has had early discussions with potential buyers about its Cerenovus line of stroke products. Johnson & Johnson first launched Cerenovus in 2017 after it combined its acquisitions of Pulsar Vascular and Neuravi.
In September 2024, the company announced that Cerenovus would be known as Johnson & Johnson MedTech going forward. Biosense Webster, Abiomed and other medtech companies shared the same fate.
The Financial Times report emphasized that it is possible nothing will come of these early discussions. If Johnson & Johnson does not receive the offers it expects, for instance, the healthcare juggernaut could put off a sale until the market changes.
Johnson & Johnson has said it will not comment on these rumors.
Click here to read the full report from Financial Times.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.